

WHAT IS CLAIMED IS:

1. An anti-IL-23p19 antibody comprising:
 - (a) a heavy chain variable region comprising CDR1: SEQ ID NO: 9, CDR2: SEQ ID NO: 10, and CDR3: SEQ ID NO: 11; and a light chain variable region comprising CDR1: SEQ ID NO: 12, CDR2: SEQ ID NO: 13, and CDR3: SEQ ID NO: 14;
 - (b) a heavy chain variable region comprising CDR1: SEQ ID NO: 15, CDR2: SEQ ID NO: 16, and CDR3: SEQ ID NO: 17; and a light chain variable region comprising CDR1: SEQ ID NO: 18, CDR2: SEQ ID NO: 19, and CDR3: SEQ ID NO: 20;
 - (c) a heavy chain variable region comprising CDR1: SEQ ID NO: 21, CDR2: SEQ ID NO: 22, and CDR3: SEQ ID NO: 23; and a light chain variable region comprising CDR1: SEQ ID NO: 24, CDR2: SEQ ID NO: 25, and CDR3: SEQ ID NO: 26; or
 - (d) a heavy chain variable region comprising CDR1: SEQ ID NO: 27, CDR2: SEQ ID NO: 28, and CDR3: SEQ ID NO: 29; and a light chain variable region comprising CDR1: SEQ ID NO: 30, CDR2: SEQ ID NO: 31, and CDR3: SEQ ID NO: 32.
2. The anti-IL-23p19 antibody of claim 1, wherein the antibody comprises:
 - (a) a heavy chain variable region sequence of SEQ ID NO: 1 and a light chain variable region sequence of SEQ ID NO: 2;
 - (b) a heavy chain variable region sequence of SEQ ID NO: 3 and a light chain variable region sequence of SEQ ID NO: 4;
 - (c) a heavy chain variable region sequence of SEQ ID NO: 5 and a light chain variable region sequence of SEQ ID NO: 6; or
 - (d) a heavy chain variable region sequence of SEQ ID NO: 7 and a light chain variable region sequence of SEQ ID NO: 8.
3. The anti-IL-23p19 antibody of claim 1, wherein the antibody is an anti-human IL-23p19 antibody.
4. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a full-length antibody.
5. The anti-IL-23p19 antibody of claim 1, wherein the antibody is an antibody fragment.

6. The anti-IL-23p19 antibody of claim 4, wherein the antibody fragment is selected from the group consisting of: Fab, Fab', F(ab)2, Fd, Fv, scFv and scFv-Fc fragment, a single-chain antibody, a minibody, and a diabody.
7. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a monoclonal antibody.
8. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a human antibody.
9. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a murine antibody.
10. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a chimeric antibody.
11. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a bispecific antibody.
12. The anti-IL-23p19 antibody of claim 1, wherein the antibody is a humanized antibody.
13. The anti-IL-23p19 antibody of claim 1, wherein the antibody does not bind the p40 subunit of IL-12.
14. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
15. A method of treating or preventing an immune-mediated inflammatory disease, the method comprising administering the antibody of claim 1 to a patient in need thereof.
16. An isolated polynucleotide comprising a sequence encoding an anti-IL-23p19 antibody according to claim 1.

17. An isolated polynucleotide according to claim 16, encoding a sequence as set forth in any one of SEQ ID NOs. 1, 3, 5, or 7.

18. A vector comprising a polynucleotide according to claim 16.

19. A cell comprising a polynucleotide according to claim 16, and/or a vector according to claim 17.

20. A method for the production of an anti-IL-23p19 antibody according to claim 1, the method comprising culturing the cell of claim 19.